Trial Profile

NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umirolimus (Primary) ; Everolimus
Indications Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
Focus Therapeutic Use
Acronyms NEXT

Most Recent Events

01 Apr 2025 Results of sub study elucidating differences in coronary vascular tissue response in the stent and peripheral sites after stent implantation between NOBORI biolimus-eluting (BES) and XIENCE V/PROMUS everolimus-eluting stent (EES) using IB-IVUS published in the Heart and Vessels
09 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
31 Mar 2014 Results for vascular healing presented at the 63rd Annual Scientific Session of the American College of Cardiology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com